Evaluation and management of atrial fibrillation

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 6, Issue 4, 2006, Pages 233-244

  Ali, Sheharyar ^a   Hong, Mauricio ^b   Antezano, Eduardo S ^a   Mangat, Iqwal ^c  

^a UNIVERSITY OF IOWA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antiarrhythmic; Antithrombotic Therapy; C reactive protein (CRP); Effective refractory period (ERP); Left atrium (LA); Stroke risk factors

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIGOXIN; DOFETILIDE; FLECAINIDE; IBUTILIDE; IDRAPARINUX; IRBESARTAN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROPAFENONE; SOTALOL; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

AGE; ANTICOAGULATION; BLEEDING DISORDER; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; EMBOLISM; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEART RATE; HIGH RISK PATIENT; HUMAN; INCIDENCE; LONG TERM CARE; MANAGED CARE; META ANALYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRESCRIPTION; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 33845461273     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152906779010728     Document Type: Review

References (102)

1. Kannel, W.B., Abbott, R.D., Savage, D.D., McNamara, P. M. Epidemiological features of chronic atrial fibrillation: the Framingham study. N. Engl. J. Med., 1982, 306, 1018-1022.
2. Falk, R.H., Atrial Fibrillation. N. Engl. J. Med., 2001, 344, 1067-78.
3. Benjamin, E.J., Wolf, P.A., D'Agostino, R.B., Silbershatz, H., Kannel, W.B., Levy, D., Impact of atrial fibrillation on the risk of death; the Framingham Study. Circulation, 1998, 98, 946-952.
4. Fuster, V., Ryden, L.E., Asinger, R.W., Cannom, D.S., Crijns, H.J., Frye, R.L., Halperin, J.L., Kay, G.N., Klein, W.W., Lévy, S., McNamara, R.L., Prystowsky, E.N., Wann, L.S., Wyse, D.G., Gibbons, R.J., Antman, E.M., Alpert, J.S., Faxon, D.P., Fuster, V., Gregoratos, G., Hiratzka, L.F., Jacobs, A.K., Russell, R.O., Smith, Jr., S.C., Klein, W.W., Alonso-Garcia, A., Blomström-Lundqvist, C., de Backer, G., Flather, M., Hradec, J., Oto, A., Parkhomenko, A., Silber, S., Torbicki, A. American College of Cardiology/American Heart Association Task Committee for Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology. Circulation, 2001, 104, 2118-50.
5. Feinberg, W. M., Blackshear, J. L., Laupacis, A., Kronmal, R., Hart R.G. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implication. Arch. Intern. Med., 1995, 155, 469-73.
6. Go, A.S., Hylek, E,M,. Philips, K.A., Chang, Y., Henault, L.E., Selby, J. V., Singer, D.E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention; AnTicoagulation and Risk Factors in Atrial fibrillation study (ATRIA). JAMA, 2001, 285, 2370-5.
7. Chugh, S.S., Blackshear, J.L., Shen, W.K., Hammill, S.C., Gersh, B.J. Epidemiology and natural history of atrial fibrillation; clinical implications. J. Am. Coll. Cardiol., 2001, 37, 371-8.
8. Benjamin, E.J., Levy, D., Vaziri, S.M., D'Agostino, R.B., Belanger, A.J., Wolf, P.A. Independent risk factors for atrial fibrillation in a population-bases chohort. The Framingham Heart Study. JAMA, 1994, 271, 840-4.
9. Klein, G.J., Bashore, T.M., Sellers, T.D., Pritchett, E.L., Smith, W.M., Gallagher, J.J. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N. Engl. J. Med., 1979, 301, 1080-1085.
10. Mukamal, K.J., Tolstrup, J.S., Friberg, J., Jensen, G., Grønbæk, M. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation, 2005, 112, 1736-42.
11. Cranefield, P., Aronson, R. Cardiac Arrhythmias: The Role of Triggered Activity and Other Mechanism. New York, NY: Futura; 1988.
12. Haïssaguerre, M., Jaïs, P., Shah, D.C., Takahashi, A., Hocini, M., Quiniou, G., Garrigue, S., Mouroux, A.L., Métayer P.L., Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med., 1998, 339, 659-666.
13. Mandapati, R., Skanes, A., Chen, J., Berenfeld, O., Jalife, J. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation, 2000, 101, 194-199.
14. Hobbs, W.J., Van Gelder, I.C., Fitzpatrick, A.P., Crijns, H.J., Garrat, C.J. The role of atrial electrical remodeling in the progression of focal atrial ectopy to persistent atrial fibrillation. J. Cardiovasc. Electrophysiol., 1999, 10, 866-870.
15. Wijffels, M.C.E.F., Kirchhof, C.J.H.J., Dorland, R., Allessie, M.A. Atrial fibrillation begets atrial fibrillation: a study in awake, chronically instrumented goats. Circulation, 1995, 92, 1954-1968.
16. Waldo, A.L. Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin? Cardiovasc. Res., 2002, 54, 217-29.
17. Timmermans, C., Rodriguez, L.M., Smeets, J.L., Wellens, H.J.J. Immediate reinitiation of atrial fibrillation following internal atrial defibrillation. J. Cardiovasc. Electrophysiol., 1998, 9, 122-128.
18. Franz, M.R. Mechano-electrical feedback. Cardiovasc. Res., 2000, 45, 263-266.
19. Aime-Sempe, C., Folliguet, T., Rucker-Martin, C., Krajewska, M., Krajewski, S., Heimburger, M., Aubier, M., Mercadier, J.J., Reed, J.C., Hatem, S.N. Myocardial cell death in fibrillating and dilated human right atria. J. Am. Coll. Cardiol., 1999, 34, 1577-1586.
20. Black, I.W., Chesterman, C.N., Hopkins, A.P., Lee, L.C., Chong, B.H., Walsh, W.F. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J. Am. Coll. Cardiol., 1993, 21, 451-457.
21. The Stroke Prvention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with non-valvular atrial fibrillation. Ann. Intern. Med., 1998, 128, 639-647.
22. Goldshimth, I., Kumar, P., Carter, P., Blann, A.D., Patel, R.L., Lip, G.Y.H. Atrial enocardial changes in mitral valve disease: a scanning electron microscopy study. Am. Heart J., 2000, 140, 777-784.
23. Shirani, J., Alaeddini, J. Structural remodeling of the left atrial appendage in patients with chronic non valvular atrial fibrillation: implications for thrombus formation, systemic embolism and assessment by transesophageal echocardiography. Cardiovasc. Pathol., 2000, 9, 97-101.
24. Frustaci, A., Chimenti, C., Bellocci, F., Morgante, E., Russo, M.A., Maseri, A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 1997, 96, 1180-1184.
25. Chung, M.K., Martin, D.O., Sprecher, D., Wazni, O., Kanderian, A., Carnes, C.A., Bauer, J.A., Tchou, P.J., Niebauer, M.J., Natale, A., Van Wagoner, D.R. C-Reactive Protein Elevation in Patients With Atrial Arrhythmias. Inflammatory Mechanisms and Persistence of Atrial Fibrillation. Circulation, 2001, 104, 2886-2891.
26. Aviles, R.J., Martin, D.O., Apperson-Hansen, C., Houghtaling, P.L., Rautaharju, P., Kronmal, R.A., Tracy, R.P., Van Wagoner, D.R., Pasty, B.M., Lauer, M.S., Chung. M.K. Inflammation as a Risk Factor for Atrial Fibrillation. Circulation, 2003, 108, 3006-3010.
27. Roldan, V., Marin, F., Blann, A.D., García, A., Marco, P., Sogorb, F., Lip G.Y.H. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur. Heart J., 2003, 24, 1373-1380.
28. Fukuchi, M., Watanabe, J., Kumagai, K., Katori, Y., Baba, S., Fukuda, K., Yagi, T., Iguchi, A., Yokoyama, H., Miura, M., Kagaya, Y., Sato, S., Tabayashi K., Shirito, K. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J. Am. Coll. Cardiol., 2001, 37, 1436-1442.
29. Nakamura, Y., Nakamura, K., Fukushima-Kusano, Ohta, K.K., Matsubara, H., Hamuro, T., Yutani C., Ohe, T. Tissue factor expression in atrial endothelia associated with non-valvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb. Res., 2003, 111, 137-142.
30. Chung, N., Belgore, F., Li-Saw-Hee, F.L., Conway, D.S.G., Blann, A.D., Lip, G.Y.H. Is the Hypercoagulable State in Atrial Fibrillation Mediated by Vascular Endothelial Growth Factor? Stroke, 2002, 33, 2817-2191.
31. Kumagai, K., Fukuami, M., Ohmori, M., Kitabatake, A., Kamada, T., Hoki, N. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J. Am. Coll. Cardiol., 1990, 16, 377-380.
32. Daoud, E.G., Weiss, R., Bahu, M., Knight, B.P., Bogun, F., Goyal, R., Harvey, M., Strickberger, S.A., Man, K.C., Morady, F. Effect of an irregular ventricular rhythm on cardiac output. Am. J. Cardiol., 1996, 78, 1433-1436.
33. Goette, A., Honeycutt, C., Langberg, J.J. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation., 1996, 94, 2968-2974.
34. Lemery, R., Brugada, P., Cheriex, E., Wellens, H.J. Reversibility of tachycardia-induced left ventricular dysfunction after closed-chest catheter ablation of the atrioventricular junction for intractable atrial fibrillation. Am. J. Cardiol., 1987, 60, 1406-1408.
35. Savelieva, I.A., Camm, A.J. Silent atrial fibrillation - another Pandora's box. Pacing Clin. Electrophysiol., 2000, 23, 145-148.
36. Page, R.L., Tilsch, T.W., Connolly, S.J., Schnell, D.J., Marcello, S.R., Wilkinson, W.E., Pritchett, E.L.C. for the Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or "silent" atrial fibrillation:frequency in untreated patients and patients receiving azimilide. Circulation, 2003, 107, 1141-5.
37. Israel, C. W., Gronefeld, G., Ehrlich, J.R., Li, Y.G., Hohnloser, S.H. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J. Am. Coll. Cardiol., 2004, 43, 47-52.
38. Wolf, P.A., Kannel, W.B., McGee, D.L., Meeks, S.L., Bharucha, N.E., McNamara, P.M. Duration of atrial fibrillation and imminence of stroke: the Framingham Study. Stroke, 1983, 14, 664-667.
39. Wolf, P.A., Abbott, R.D., Kannel, W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch. Intern. Med., 1987, 147, 1561-1564.
40. Kopecky, S.L., Gersh, B.J., McGoon, M.D., Whisnant, J.P., Holmes, D.R., Ilstrup, D.M., Frye, R.L. The natural history of lone atrial fibrillation. A population based study over three decades. N. Engl. J. Med., 1987, 317, 669-74.
41. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial). Lancet, 1993, 342, 1255-62.
42. Hart, R.G., Pearce, L.A., Rothbart, R.M., McAnulty, J.H., Asinger, R.W., Halperin, J.L. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J. Am. Coll. Cardiol., 2000, 35, 183-187.
43. Ezekowitz, M.D., James, K.E., Nazarian, S.M., Davenport, J., Broderick, J.P., Gupta, S.R., Thadani, V., Meyer, M.L., Bridgers, S.L. Silent cerebral infarction in patients with non-rheumatic atrial fibrillation. Circulation, 1995, 92, 2178-82.
44. Ezekowitz, M.D., Levine, J.A. Prefenting stroke in patients with atrial fibrillation. JAMA, 1999, 281, 1830-1835.
45. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation; analysis of pooled data from five randomized controlled trials. Arch. Intern. Med., 1998, 154, 1449-1457.
46. Hart, R.G., Pearce, L.A., McBride, R., Rothbart, R.M., Asinger, R.W. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation; analysis of 2012 participant in the SPA I-III clinical trials. The stroke prevention in atrial fibrillation (SPAF) investigators. Stroke, 1999, 30, 1223-9.
47. Gage, B.F., Waterman, A.D., Shannon, W., Boechler, B., Rich, M.W., Radford, M.J. Validation of clinical schemes for predicting stroke: results from National Registry of Atrial Fibrillation. JAMA, 2001, 285, 2864-70.
48. Wang, T.J., Massaro, J.M., Levy, D., Vasan, R.S., Wolf, P.A., D'Agostino, R.B., Larson, M.G., Kannel, W.B., Benjamin, E.J. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham heart Study. JAMA, 2003, 290, 1049-1056.
49. Peterson, P., Boysen, G., Godtfredsen, J., Andersen, E.D., Andersen, B. Placebo-controlled randomized trial of warfarin and aspirin for prevention of thromboembolic complication in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet, 1989, 1, 175-9.
50. The Boston Area Anticoagulation Trials of Atrial Fibrillation Investigator. The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med., 1990, 323, 1505-11.
51. Stroke Prevention in Atrial Fibrillaion Investigator. Stroke prevention in atrial fibrillation study: final result. Circulation, 1991, 84, 527-39.
52. Connolly, S.J., Laupacis, A., Gent, M., Roberts, R.S., Cairns, J.A., Joyner, C. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J. Am. Coll. cardiol., 1991, 18, 349-55.
53. Ezekowitz, M.D., Bridgers, S.L., James, K.E., Carliner, N.H., Colling, C.L., Gornick, C.C., Krause-Steinrauf, H., Kurtzke, J.F., Nazarian, S.M., Radford, M.J. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N. Engl. J. Med., 1992, 327, 1406-12.
54. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke: EAFT (European Atrial Fibrillation Trial). Lancet, 1993, 342, 1255-62.
55. Hart, R.G., Benavente, O., McBride, R., Pearce, L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med., 1999, 131, 492-501.
56. Hylek, E.M., Singer, D.E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann. Intern. Med., 1994, 120, 897-902.
57. Albers, G.W., Dalen, J., E, Laupacis. A., Manning, W.J., Petersen, P., Singer, D.E. Antithrombotic therapy in atrial fibrillation. Chest, 2001, 119, 194S-206S.
58. The European Atrial Fibrillation Trial. Optimal oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N. Engl. J. Med., 1995, 333, 5-10.
59. Hylek, E.M., Skates, S.J., Sheehan, M.A., Singer, D.E. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N. Engl. J. Med., 1996, 335, 540-546.
60. Hylek, E.M., Go, A.S., Chang, Y., Jensvold, J.G., Renault, L.E., Selby, J. V., Singer, D.E. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Eng. J. Med., 2003, 349, 1019-1026.
61. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324, 71-86.
62. The Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials. Arch. Intern. Med., 1997, 157, 1237-40.
63. Bo, S., Cicone, G., Scaglione, L., Taliano, C., Piobbici, M., Merletti, F., Pagano, G. Warfarin for non-valvular atrial fibrillation: still underused in the 21st century? Heart, 2003, 89, 553-554.
64. Dobesh, P.P. Ximelagatran: pharmacology, pharmacokinetics, and pharmacodynamics. Pharmacotherapy, 2004, 24(10 Pt 2), 169S-178S.
65. Olsson, S.B. Executive Steering Committee on hehalf of he SPORTIF III investigators. Stroek prevention with the oral direct thrombin inhibitor, SPORTIF II Investigators fibrillation (SPORTIF III), randomized controlled trial. Lancet, 2003, 362, 1691-8.
66. Halprein, J.L. SPORTIF III and V Study Investigators. Efficacy and safety of oral direct thrombin inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation (SPORTIF V). AHA Plenary Session V11.
67. Kaul, S., Diamond, G.A., Weintraub, W. S. Trials and tribulations of non-inferiority the ximelagatran experience. J. Am. Coll. Cardiol., 2005, 46, 1986-95.
68. National Institutes of Health/National Library of Medicine. A safety and efficacy trial evaluating the use of SanOrg34006 compared to warfarin or acenocoumaril in patients with atrial fibrillation. Available at: www.clinicaltrials.gov.
69. Hohnloser, S.H., Connolly, S.J. Combined antiplatelet therapy in atrial fibrillation: review of literature and future avenues. J. Cardiovasc. Electrophysiol., 2003, 14 (Suppl.), 560-563.
70. ACC/AHA guidelines for the management of valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 1998, 1486-588.
71. Sievert, H., Lesh, M.D., Trepels, T., Omran, H., Bartorelli, A., Bella, P.D., Nakai, T., Reisman, M., DiMario, C., Block, P., Kramer, P., Fleschenberg, D., Krumsdorf, U., Scherer, D. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation, 2002, 105, 1887-9.
72. Hagens, V., Van Gelder, I., Crijins, H. The RACE study in perspectiva of randomized studies on management of persistent atrial fibrillation. Cardiac. Electrophysiol. Rev., 2003, 7, 118-121.
73. Farshi, R., Kistner, D., Sarma, J.S., Longmate, J.A., Singh, B.N. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J. Am. Coll. Cardiol., 1999, 33, 304-310.
74. Nichol, G., McAlister, F., Pham, B., Laupacis, A., Shea, B., Green, M., Tang, A., Wells, G. Meta-analysis of randomized controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart, 2002, 87, 535-49.
75. Singh, B.N., Singh, S.N., Reda, D.J., Tang, X.C., Lopez, B., Harris, C.L., Fletcher, R.D., Sharma, S.C., Atwood, J.E., Jacobson, A.K., Lewis, Jr. H.D., Raisch, D.W., Ezekowitz, M.D. Amiodarone versus sotalol for atrial fibrillation. N. Engl. J. Med., 2005, 352, 1861-1872.
76. Folk, R., Pollak, A., and Singh, S. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J. Am. Coll. Cardiol., 1997, 29, 385-90.
77. Ellenbogen, K., Stambler, B., Wood, M. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study, J. Am. Coll. Cardiol., 1996, 28, 130-6.
78. Alboni, P., Botto, G.L., Baldi, N., Luzi, M., Russo, V., Gianfranchi, L., Marchi, P., Calzolari, M., Solano, A., Baroffio, R., Gaggioli, G. Out-of-hospital treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N. Engl. J. Med., 2004, 351, 2384-2391.
79. Roy, D., Talajic, M., Dorian, P., Connolly, S., Eisenberg, M.J., Green, M., Kus, T., Lambert, J., Dubuc, M., Gagné, P., Nattel, S., Thibault, B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N. Engl. J. Med., 2000, 342, 913-20.
80. Reimold, S.C., Cantillon, C.O., Friedman, P.L., Antman, E.M. Propafenone versus sotalol for suppression recurrent symptomatic atrial fibrillation. Am. J. Cardiol., 1993, 71, 558-63.
81. Cox, J.L., Boineau, J.P., Schuessler, R.B., Kater, K.M., Lappas, D.J. Five years experience with the maze procedure for patients with atrial fibrillation. Ann. Thorac. Surg., 1993, 56, 814-23.
82. Jais, P., Haissaguerre, M., Shah, D.C., Chouairi, S., Gencel, L., Hocini, M., Clementy, J. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation, 1997, 95, 572-576.
83. Hsu, L-F., Jais, P., Sanders, P., Garrigue, S., Hocini, M., Sacher, F., Takahashi, Y., Rotter, M., Pasquié, JL., Scavée, C., Bordachar, P., Clémenty, J., Haïssaguerre, M. Catheter ablation for atrial fibrillation in congestive heart failure. N. Engl. J. Med., 2004, 351, 2373-3107.
84. Saxonhouse, S.J., Curtis, A.B. Risks and benefits of rate control versus maintenance of sinus rhythm. Am. J. Cardiol., 2003, 91 (suppl.), 27D-32D.
85. Hohnloser, S.H., Kuck, K.H., Lilienthal, J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet, 2000, 356, 1789-1794.
86. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med., 2002, 347, 1825-1833.
87. Van Gelder, I.C., Hagens, V.E., Bosker, H.A., Kingma, J.H., Kamp, O., Kingma, T., Said, S.A., Darmanata, J.I., Timmermans A.J.M., Tijssen, J.G.P., Crijns, H.J.G.M. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med., 2002, 347, 1834-1840.
88. Carlsson, J., Miketic, S., Windeler, J., Cuneo, A., Haun, S., Micus, S., Walter, S., Tebbe, U. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am. Coll. Cardiol., 2003, 41, 1690-1696.
89. Opolski, G., Torbicki, A., Kosior, D., Szulc, M., Wozakowska-Kaplon, B., Kolodziej, P., Achremczyk, P. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest., 2004, 126, 476-486.
90. de Denus, S., Sanoski, C.A., Carlsson, J., Opolski, G., Spinler, S.A. Rate vs Rhythm Control in Patients With Atrial Fibrillation: A Meta-analysis. Arch. Intern. Med., 2005, 165 (3), 258-262.
91. Savelieva, I., Camm, A.J. Clinical relevance of silent atrial fibrillation; prevalence, prognosis, quality of life and management. J. Interv. Card. Electrophysiol., 2000, 4, 369-382.
92. Gallagher, M.M., Guo, X.H., Poloniecki, J.D., Yap, Y.G., Ward, D., Camm, A.J. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation. J. Am. Coll. Cardiol., 2001, 38, 1498-504.
93. Dittrich, H.C., Erikson, J.S., Schneideman, T., Blacky, A.R., Savides, T., Nicod, P.H. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am. J. Cardiol., 1989, 63, 193-7.
94. Dalzell, G.W., Anderson, J., Adgey, A.A. Factors determining success and energy requirement for cardioversion of atrial fibrillation. Q. J. Med., 1990, 76, 903-13.
95. Kirchhof, P., Eckardt, L., Loh, P., Weber, K., Fischer, R.J., Seidl, K.H., Bocker, D., Breithardt, G., Haverkamp, W., Borggrefe, M. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation. Lancet, 2002, 360, 1275-9.
96. Page, R.L., Kerber, R.E., Russell, J.K., Trouton, T., Waktare, J., Gallik, D., Olgin, J.E., Ricard, P., Dalzell, G.W., Reddy, R., Lazzara, R., Lee, K., Carlson, M., Halperin, B., Bardy, G.H. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation. The result of an international randomized, double blind multicenter trial. J. Am. Coll. Cardiol., 2002, 39, 1956-63.
97. Oral, H., Souza, J.J., Michaud, G.F., Knight, B.P., Goyal, R., Strickberger, S.A., Morady, F. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N. Engl. J. Med., 1999, 340, 1849-54.
98. Capucci, A., Villani, G.O., Aschieri, D., Rosi, A., Piepoli, M.F. Oral amiodarone increases the efficacy of direct current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur. Heart J., 2000, 21, 66-73.
99. Boriani, G., Diemberger, I., Biffi, M., Martignani C., Branzi, A. Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs., 2004, 64, 2741-62.
100. Bjerkelund, C.J., Oming, O.M. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am. J. Cardiol., 1969, 23, 208-16.
101. Klein, A.L., Grimm, R.A., Murray, R.D., Apperson-Hansen, C., Asinger, RW., Black, IW., Davidoff, R., Erbel, R., Halperin, J.L., Orsinelli, D.A., Porter, T.R., Stoddard, M.F. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N. Eng. J. Med., 2001, 344, 1411-20.
102. Berger, M., Schweitzer, P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter; a retrospective analysis. Am. J. Cardiol., 1998, 82, 1545-7.